A Potent and Selective Quinolone-Based PTPN22 Inhibitor with Improved Immunotherapeutic Activity.

Area of Science:

• Immunology
• Pharmacology
• Medicinal Chemistry

Background:

• Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) negatively regulates T cell signaling and antitumor immune responses.
• Abrogating PTPN22 function enhances T cell activation, offering a target for cancer immunotherapy.

Purpose of the Study:

• To design, synthesize, and evaluate novel quinolone-3-carboxylic acid-based PTPN22 inhibitors.
• To identify a lead compound with improved potency, selectivity, pharmacokinetics, and in vivo efficacy compared to existing inhibitors.

Main Methods:

• Structure-activity relationship (SAR) studies of quinolone-3-carboxylic acid derivatives.
• In vitro cellular assays to assess PTPN22 inhibition and T cell function.
• In vivo studies using MC38 tumor models to evaluate tumor growth inhibition and antitumor immunity.

Main Results:

• A novel series of PTPN22 inhibitors based on the quinolone-3-carboxylic acid scaffold was synthesized.
• Compound L-32 demonstrated enhanced potency, selectivity, and cellular efficacy over the previous inhibitor L-1.
• L-32 exhibited improved pharmacokinetic properties, including oral bioavailability, and superior reduction of MC38 tumor growth in vivo.

Conclusions:

• L-32 represents a promising lead molecule for developing novel anticancer agents targeting PTPN22.
• Inhibition of PTPN22 with L-32 promotes robust antitumor immunity, leading to reduced tumor burden.
• The developed quinolone-3-carboxylic acid-based inhibitors offer a new therapeutic strategy for cancer treatment.